<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: The INNO-LIA ANA Update is a qualitative multiparameter line immunoassay for detection of autoantibodies to several different antigens associated with <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We sought to optimize and validate the cut-off values for its antigen-specific components: SmB, SmD, RNP-70k, RNP-A, RNP-C, SSA/Ro52, SSA/Ro60, SSB/La, Cenp-B, Topo-I, Jo-1, ribosomal P, and <z:chebi fb="0" ids="15358">histones</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Our aim was to achieve 98% specificity for each of the markers, with respect to differential disease controls, while maintaining sensitivity </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: For optimization, the cut-off value of the different antigen lines was fixed to achieve this specificity using an in-house set of 955 patient samples </plain></SENT>
<SENT sid="4" pm="."><plain>Specificity was validated at multiple sites using a different set of 330 samples obtained from 158 apparently healthy blood donors, 100 patients with a variety of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, 20 each with Wegener's <z:hpo ids='HP_0002955'>granulomatosis</z:hpo>, <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel disease</z:e>, and <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e>, and 12 with psoriatic <z:hpo ids='HP_0001369'>arthritis</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Sensitivity was evaluated, using this optimized cut-off control, in 147 patients with <z:hpo ids='HP_0100324'>scleroderma</z:hpo>, 93 with <z:e sem="disease" ids="C1527336" disease_type="Disease or Syndrome" abbrv="">Sj√∂gren's disease</z:e>, 40 with <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo>, 40 with <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo>, 39 with <z:e sem="disease" ids="C0026272" disease_type="Disease or Syndrome" abbrv="MCTD">mixed connective tissue disease</z:e>, and 19 with <z:e sem="disease" ids="C0085655" disease_type="Disease or Syndrome" abbrv="">polymyositis</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Sensitivity and specificity of the INNO-LIA ANA Update were determined using the clinical diagnosis as reference </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: The optimized cut-off values resulted in a specificity 98% or more for <z:hpo ids='HP_0000001'>all</z:hpo> LIA markers except one (<z:chebi fb="0" ids="15358">histones</z:chebi> 97.8%) in the validation set of 330 samples </plain></SENT>
<SENT sid="8" pm="."><plain>The sensitivity for each marker tested in 378 samples from the target patient groups was comparable to that reported in the literature </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: The INNO-LIA ANA Update shows uniformly high specificities combined with sensitivities very similar to those of reference assays, in a single test format </plain></SENT>
</text></document>